OTCMKTS:BIXT Bioxytran (BIXT) Stock Price, News & Analysis $0.14 +0.01 (+6.47%) As of 06/3/2025 03:54 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock About Bioxytran Stock (OTCMKTS:BIXT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Bioxytran alerts:Sign Up Key Stats Today's Range$0.13▼$0.1450-Day Range$0.10▼$0.1852-Week Range$0.06▼$0.23Volume169,993 shsAverage Volume241,575 shsMarket Capitalization$12.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was founded in 2008 and is headquartered in Needham, Massachusetts.Read More… Bioxytran Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks19th Percentile Overall ScoreBIXT MarketRank™: Bioxytran scored higher than 19% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Bioxytran. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Bioxytran is -13.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bioxytran is -13.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.01% of the outstanding shares of Bioxytran have been sold short.Short Interest Ratio / Days to CoverBioxytran has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bioxytran has recently decreased by 66.40%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioxytran does not currently pay a dividend.Dividend GrowthBioxytran does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.01% of the outstanding shares of Bioxytran have been sold short.Short Interest Ratio / Days to CoverBioxytran has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bioxytran has recently decreased by 66.40%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News Sentiment0.34 News SentimentBioxytran has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Bioxytran this week, compared to 0 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bioxytran insiders have not sold or bought any company stock.Percentage Held by Insiders70.00% of the stock of Bioxytran is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Bioxytran's insider trading history. Receive BIXT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bioxytran and its competitors with MarketBeat's FREE daily newsletter. Email Address BIXT Stock News HeadlinesBioxytran’s Groundbreaking Stroke & Alzheimer’s Tech Gains Validation That Measures Oxygenation Uptake During StrokesJune 3 at 3:01 PM | finance.yahoo.comBioxytran's Groundbreaking Stroke & Alzheimer's Tech Gains Validation That Measures Oxygenation Uptake During StrokesJune 3 at 9:12 AM | globenewswire.comElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly becoming one of the most profitable stories of the year.June 4, 2025 | True Market Insiders (Ad)Bioxytran’s Antiviral Breakthrough Featured in University of Georgia’s $100M HPAI Poultry Innovation Grand Challenge SubmissionMay 21, 2025 | finance.yahoo.comBioxytran's Antiviral Breakthrough Featured in University of Georgia's $100M HPAI Poultry Innovation Grand Challenge SubmissionMay 21, 2025 | globenewswire.comBIOXYTRAN, INC.: Bioxytran Completes Dose Optimization of Antiviral, ProLectin-MMay 12, 2025 | finanznachrichten.deBioxytran Completes Dose Optimization of Antiviral, ProLectin-MMay 12, 2025 | globenewswire.comBioxytran Marks 50 years of Mitochondrial Research with BXT-25 AdvancementsApril 11, 2025 | globenewswire.comSee More Headlines BIXT Stock Analysis - Frequently Asked Questions How have BIXT shares performed this year? Bioxytran's stock was trading at $0.0899 at the beginning of 2025. Since then, BIXT stock has increased by 55.6% and is now trading at $0.1399. View the best growth stocks for 2025 here. How were Bioxytran's earnings last quarter? Bioxytran, Inc. (OTCMKTS:BIXT) posted its quarterly earnings results on Thursday, May, 15th. The company reported ($0.02) earnings per share (EPS) for the quarter. How do I buy shares of Bioxytran? Shares of BIXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bioxytran own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bioxytran investors own include AMC Entertainment (AMC), Armata Pharmaceuticals (ARMP), bluebird bio (BLUE), Esports Entertainment Group (GMBL), Genius Group (GNS), Novavax (NVAX) and Karora Resources Inc. (RNX.TO) (RNX). Company Calendar Last Earnings5/15/2025Today6/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:BIXT CIK1445815 Webwww.bioxytraninc.com Phone(617) 454-1199FaxN/AEmployees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$4.47 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-2,100.34% Debt Debt-to-Equity RatioN/A Current Ratio0.03 Quick Ratio0.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-7.00Miscellaneous Outstanding Shares88,992,000Free Float26,440,000Market Cap$12.45 million OptionableNot Optionable Beta1.82 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (OTCMKTS:BIXT) was last updated on 6/4/2025 by MarketBeat.com Staff From Our PartnersThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredFPV Drone Innovator Secures Major Defense ContractIn May, Ukraine launched Operation Spider Web - a 117-drone FPV swarm that devastated Russian fuel depots and ...The Tomorrow Investor | SponsoredJunior Explorer Taps Into TSMC’s $165 Billion Chip CorridorThe chip war is moving underground. As the U.S. ramps up semiconductor production to outpace China, an unex...Capital Trends | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe Recession Already Started, Are You Prepared?Global central banks are stockpiling gold. Billionaires are hedging with precious metals. And thousands of Ame...Lear Capital | SponsoredThe Real Reason Silver Prices Are SoaringElon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioxytran, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioxytran With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.